Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. An Open, Randomized Multi-center Study.

NCT00318552 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00318552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00318552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. An Open, Randomized Multi-center Study.
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2002
Completion date
June 30, 2006
Enrollment
160
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis